2020
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia
Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal Of Hematology 2020, 113: 92-99. PMID: 32951163, DOI: 10.1007/s12185-020-02994-8.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCell Cycle ProteinsDecitabineDose-Response Relationship, DrugFebrile NeutropeniaFeeding and Eating DisordersFemaleGene ExpressionHumansLeukemia, Myeloid, AcuteMaleMolecular Targeted TherapyProtein Serine-Threonine KinasesProto-Oncogene ProteinsPteridinesTreatment OutcomeConceptsAcute myeloid leukemiaMyeloid leukemiaCommon treatment-emergent adverse eventsPhase 1 dose-escalation trialTreatment-emergent adverse eventsMTD of volasertibObjective response rateAdverse event profileDose-escalation trialPhase 1 trialAnti-leukemic activityPolo-like kinase 1Febrile neutropeniaEscalation trialAdverse eventsCell cycle kinase inhibitorsAML patientsEvent profilePoor prognosisResponse ratePatientsVolasertibDecitabineKinase inhibitorsNumerous cancers
2018
The genetic and molecular pathogenesis of myelodysplastic syndromes
Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. European Journal Of Haematology 2018, 101: 260-271. PMID: 29742289, DOI: 10.1111/ejh.13092.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMolecular pathogenesisGene expression profilingSignal transduction elementsDevelopment of MDSHigh-throughput techniquesCohesin proteinsMyelodysplastic syndromeRNA splicingDNA methylationTranscription factorsDNA repairMolecular basisExpression profilingMalignant myeloid disordersBone marrow microenvironmentGenetic materialClonal architectureSuch mutationsTransduction elementsInflammatory bone marrow microenvironmentMarrow microenvironmentImportant substrateGenetic mutationsDiverse groupPathophysiology of MDS
2016
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States
Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia & Lymphoma 2016, 58: 982-985. PMID: 27558206, DOI: 10.1080/10428194.2016.1214954.Peer-Reviewed Original ResearchEmerging biological therapies for the treatment of myelodysplastic syndromes
Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion On Emerging Drugs 2016, 21: 283-300. PMID: 27486848, DOI: 10.1080/14728214.2016.1220534.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsBiological TherapyDrug DesignEpigenesis, GeneticHumansMolecular Targeted TherapyMyelodysplastic SyndromesPrognosisRNA SplicingConceptsMyelodysplastic syndromeHistone deacetylase inhibitorsTreatment optionsNovel agentsLower-risk myelodysplastic syndromesHigh-risk myelodysplastic syndromeHMA treatment failureRisk-adaptive therapySignificant clinical activityNovel treatment optionsNovel effective therapiesNovel therapeutic approachesHMA failureBiological therapyTreatment failureBone marrow nicheClinical trialsEffective therapyClinical activityImmune responseTherapeutic approachesSurvival advantageFuture therapiesImmune systemDeacetylase inhibitors
2014
Hepatocellular carcinoma: systemic therapies and future perspectives
Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Review Of Anticancer Therapy 2014, 14: 1205-1218. PMID: 25199765, DOI: 10.1586/14737140.2014.949246.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdultCarcinoma, HepatocellularHepatitis CHumansImmunotherapyLiver CirrhosisLiver NeoplasmsLiver TransplantationMolecular Targeted TherapyObesitySurvival RateConceptsHepatitis C virus infectionC virus infectionIncidence of HCCMedian survival timeCommon primary malignancyCancer-related deathCommon solid cancersFuture therapeutic directionsUnresectable diseaseLiver transplantationLocoregional therapyPrimary malignancySurgical resectionSystemic therapyTreatment optionsSystemic optionsVirus infectionHepatocellular carcinomaSolid cancersSurvival timeMolecular pathogenesisTherapeutic directionsTherapyHCCPatientsBeyond hypomethylating agents failure in patients with myelodysplastic syndromes
Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion In Hematology 2014, 21: 123-130. PMID: 24335709, PMCID: PMC4124617, DOI: 10.1097/moh.0000000000000016.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDNA MethylationHematopoietic Stem Cell TransplantationHumansInduction ChemotherapyLenalidomideMolecular Targeted TherapyMyelodysplastic SyndromesPrognosisRecurrenceRetreatmentThalidomideTransplantation, HomologousTreatment FailureTreatment OutcomeConceptsMyelodysplastic syndromeAllogeneic stem cell transplantationPathogenesis of MDSOnly curative modalityStem cell transplantationCombination treatment strategiesCombination therapeutic strategiesNovel therapeutic approachesHMA failureHMA therapyCurative modalityObjective responseRelapse rateDismal prognosisProlong survivalInvestigational agentsModest efficacyCell transplantationClinical trialsTreatment strategiesTherapeutic approachesTherapeutic strategiesBiologic underpinningsMost respondersMolecular pathways